In April 2006, WHO released a report by the Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH Report).
How to reform the WHO?
The World Health Organization just published a report on this week’s second meeting of the WHO Expert Working Group (EWG) on R&D Financing.
The PAHO negotiations on the R&D resolution has produced a new draft, which radically guts the provision on transparency of pharmaceutical industry economics.
The US opposed this language:
“(j) to develop, with input from Member States, a possible standard for disclosure of economic data for drug registered for sale, including disclosures of the costs of R&D, the prices of products, and the annual revenues from the sale of products.”
The US agreed to this language:
Today the executive board of the Pan American Health Organization (PAHO) is considering a proposal to have more transparency of the economics of the pharmaceutical industry. (I have separately blogged about this on the Huffpo). Specifically, an amendment offered to a PAHO EB resolution on research, proposed the following:
This is the statement that the government of Bolivia delivered today to the 62nd World Health Assembly at the conclusion of the discussions on the Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (WHA 61.21).
Statement of Bolivia on resolving outstanding elements of agenda item 12.8
Joint Statement on behalf of
Bangladesh, Barbados, Bolivia and Suriname, and
Cuba, Ecuador, Nicaragua and Venezuela
The WHA will take up the WHA IGWG resolution at 9AM on Friday.
When discussing the issue of excluding the WHO from discussions about a medical R&D treaty, one PhRMA lobbyist told me “this was put to bed long ago.” He was in part referring to a WHO “green room” meeting that was organized before the Obama inauguration. One negotiator said the pharmaceutical companies are pressing hard to kill the medical R&D treaty here “before the new people take over.”
The WHO has just issued a statement on the transit of medicines. It is short and mild. The statement does not mention goods in transit in the title. It does not mention at all that medicines have been seized. The best part of the statement is the following quote:
Ensuring that the interests of trade and health are appropriately managed, also means that the flow of legitimate medicines, including generic medicines, is not impeded.
The action part of the statement is weak, however: